MARKET

GENB

GENB

Generate Biomedicines
NASDAQ
9.54
-0.83
-8.00%
After Hours: 9.90 +0.36 +3.77% 19:32 11/20 EST
OPEN
10.06
PREV CLOSE
10.37
HIGH
10.58
LOW
9.40
VOLUME
967.86K
TURNOVER
--
52 WEEK HIGH
22.67
52 WEEK LOW
9.40
MARKET CAP
1.23B
P/E (TTM)
-3.9158
1D
5D
1M
3M
1Y
5Y
1D
Generate Biomedicines Price Target Cut to $21.00/Share From $22.00 by Morgan Stanley
Dow Jones · 4d ago
Generate Biomedicines Is Maintained at Overweight by Morgan Stanley
Dow Jones · 4d ago
Morgan Stanley Maintains Overweight on Generate Biomedicines, Lowers Price Target to $21
Benzinga · 4d ago
Generate Biomedicines, Inc. (GENB) Gets a Buy from Morgan Stanley
TipRanks · 4d ago
Generate Biomedicines price target lowered to $21 from $22 at Morgan Stanley
TipRanks · 4d ago
AI Could Help Speed Up the Search for Better Health Treatments. That Could Be Good News for Humanity, and the Anthropic IPO.
Barchart · 4d ago
Nvidia boosts SpaceX stake, cuts Intel holding by 25% in Q3
Seeking Alpha · 5d ago
Weekly Report: what happened at GENB last week (1109-1113)?
Weekly Report · 6d ago
More
About GENB
Generate Biomedicines, Inc. is a clinical-stage generative biology company focusing on the Artificial intelligence (AI) revolution in biotechnology and drug design and development. The Company is engaged in the field of generative biology using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its Generate Platform integrates generative and predictive models that learn design principles from proprietary data and graph neural networks, among other architectures. Its lead product candidate, GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma. Its other product candidates include GB-4362, a systemically administered monoclonal antibody designed to neutralize free monomethyl auristatin E (MMAE) as an adjunctive therapy to antibody-drug conjugate (ADC) molecules with an MMAE payload, as well as GB-5267, an armored, MUC16-directed CAR-T cell therapy candidate.

Webull offers Generate Biomedicines Inc stock information, including NASDAQ: GENB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GENB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GENB stock methods without spending real money on the virtual paper trading platform.